First- and second-line bevacizumab in ovarian cancer: A Belgian cost-utility analysis.

ABSTRACT:

Background

Currently, in Belgium, bevacizumab is reimbursed for ovarian cancer patients, based on a contract between the Minister and the manufacturer including confidential agreements. This reimbursement will be re-evaluated in 2018.

Objective

To support the reimbursement reassessment by calculating the cost-effectiveness of bevacizumab: (1) in addition to first-line chemotherapy; (2) in the treatment of recurrent ovarian cancer (platinum-sensitive or platinum-resistant).

Methods

A health economic model has been developed for the Belgian situation according to the Belgian guidelines for economic evaluations. The lifetime Markov model was set up from the perspective of the health care payer (government and patient), including direct healthcare related costs. Results a

SUBMITTER: Neyt M 

PROVIDER: S-EPMC5891000 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature